To address this limitation, we developed a lipid-prodrug nanoamplifier (SIM-SS-LA NAs), composed of disulfide-linked linoleic alcohol and simvastatin (SIM) to enhance ferroptosis...Notably, the released LA acts as an exogenous substrate, substantially increasing lipid peroxide accumulation and synergizing with SIM-mediated GPX4 inhibition to amplify ferroptosis. As expected, the lipid-prodrug nanoamplifier showed potent ferroptosis-driven antitumor activity in a 4T1 breast tumor-bearing mouse model, offering an efficient nanotherapeutic strategy for ferroptosis-based cancer therapy.

12 days ago

Journal

GPX4 (Glutathione Peroxidase 4)

simvastatin

13d

Mechanisms of Qibai Pingfei Capsules in inhibiting pyroptosis of pulmonaryartery adventitial fibroblasts via regulating NLRP3/Caspase-1/ GSDMD pathway to intervene in COPD complicated by pulmonary arterial hypertension (PubMed, Zhongguo Zhong Yao Za Zhi)

Rats were divided into five groups(n=15 each), i.e., control, model, QBPF, QBPF + nigericin(NLRP3 activator), and simvastatin groups...In conclusion, QBPF attenuates lung function decline, suppresses inflammatory responses, alleviates pulmonary vascular remodeling, and intervenes in the disease progression of COPD complicated by PH in rats. Its mechanisms may be related to modulating the NLRP3/Caspase-1/GSDMD pathway to inhibit PAAF pyroptosis.

13 days ago

Journal

TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • VIM (Vimentin) • IL18 (Interleukin 18) • NLRC5 (NLR Family CARD Domain Containing 5) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)

simvastatin

13d

Declined RTN3 stabilizes DHCR7 to induce cholesterol-dependent tumor progression and MEK inhibitors insensitivity in thyroid cancer. (PubMed, Cell Death Dis)

Downregulation of RTN3 lead to stabilization of DHCR7 and elevate cholesterol concentration, activating EGFR/ERK pathway and contributes to progression of thyroid cancer, which can be rescued by HMG-CoA reductase inhibitor Simvastatin. We identified RTN3 as a tumor suppressor and a biomarker of sensitivity to MEK inhibitors and verified the role of cholesterol in drug resistance. The combination of statins provides a novel therapeutic method in patients resistant to MEK inhibitors.

13 days ago

Journal

DHCR7 (7-Dehydrocholesterol Reductase) • RTN3 (Reticulon 3)

simvastatin

14d

Clinical Evaluation of Simcyp-Guided Simvastatin Dosing in Patients With Liver Cirrhosis (clinicaltrials.gov)

P4, N=22, Completed, Kafrelsheikh University

14 days ago

New P4 trial

simvastatin

17d

ARES: Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy (clinicaltrials.gov)

P2, N=84, Recruiting, National Cancer Institute, Naples | Not yet recruiting --> Recruiting

17 days ago

Enrollment open

HER-2 (Human epidermal growth factor receptor 2) • ARID1A (AT-rich interaction domain 1A) • DPYD (Dihydropyrimidine Dehydrogenase)

HER-2 negative • ARID1A mutation

Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • simvastatin

18d

Integrated transcriptomics and molecular docking identify hub genes and statin regulators in Helicobacter pylori-associated gastric mucosal pathogenesis. (PubMed, Front Cell Infect Microbiol)

To explore potential therapeutic interventions, we performed small-molecule drug prediction and molecular docking for hub genes revealed: Simvastatin: Linked to CCL20, NFKBIA, and ICAM1. Atorvastatin: Associated with CDKN1A, ICAM1, and TNF. TPCA-1: Targeting JAK1. These findings provide a theoretical foundation for further investigation into the molecular mechanisms underlying H. pylori-related diseases.

18 days ago

Journal

BRCA1 (Breast cancer 1, early onset) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • BIRC3 (Baculoviral IAP repeat containing 3) • JAK1 (Janus Kinase 1) • TNFAIP3 (TNF Alpha Induced Protein 3) • CCL20 (C-C Motif Chemokine Ligand 20) • ICAM1 (Intercellular adhesion molecule 1) • IRF1 (Interferon Regulatory Factor 1) • ITGAM (Integrin, alpha M) • SPI1 (Spi-1 Proto-Oncogene) • ETS1 (ETS Proto-Oncogene 1) • IL17A (Interleukin 17A) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • NFKB2 (Nuclear Factor Kappa B Subunit 2) • NFKBIA (NFKB Inhibitor Alpha 2) • NFKBIE (NFKB Inhibitor Epsilon) • TRAF1 (TNF Receptor Associated Factor 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • E2F1 (E2F transcription factor 1) • EGR1 (Early Growth Response 1) • HSF1 (Heat Shock Transcription Factor 1) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit)

simvastatin • atorvastatin

19d

KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (clinicaltrials.gov)

P=N/A, N=12, Completed, Helsinki University Central Hospital | Not yet recruiting --> Completed

19 days ago

Trial completion

simvastatin • omeprazole

20d

T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer (clinicaltrials.gov)

P2, N=36, Recruiting, Medical University of South Carolina | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

20 days ago

Trial completion date • Trial primary completion date

simvastatin

21d

Paeonol alleviates atherosclerosis by inhibiting CD8+ T-cell activation via targeting the SYK/NFATc1 signaling pathway in ApoE-/- mice. (PubMed, J Ethnopharmacol)

SYK in CD8+ T-cells represents a potential therapeutic target for atherosclerosis. Pae inhibits atherosclerosis by blocking the SYK/NFATc1 pathway to reduce cytotoxic mediator release and prevent vascular endothelial cell injury.

21 days ago

Preclinical • Journal

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • SYK (Spleen tyrosine kinase) • GZMB (Granzyme B) • APOE (Apolipoprotein E) • NFATC1 (Nuclear Factor Of Activated T Cells 1)

simvastatin

21d

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis (clinicaltrials.gov)

P2, N=52, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026

21 days ago

Trial completion date

simvastatin

29d

Transcriptional and Pathway Level Heterogeneity in Luminal A Breast Cancer: A Framework for Precision Therapy. (PubMed, Arch Med Res)

Our integrative multi-omics analysis reveals the complex molecular architecture of Luminal A breast cancer, characterized by transcriptional and pathway-level heterogeneity. The findings advocate for subtype-specific therapeutic interventions targeting transcription factor networks, redox balance, and the tumor microenvironment. This systems-level framework provides a foundation for precision risk stratification and treatment optimization in Luminal A breast cancer.

29 days ago

Journal

CEBPA (CCAAT Enhancer Binding Protein Alpha) • SOX2 • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • TLX1 (T Cell Leukemia Homeobox 1)

HR positive

dexamethasone • simvastatin

SELE is associated with reduced breast cancer susceptibility: Evidence from Mendelian randomization and single-cell transcriptome. (PubMed, Transl Oncol)

This study provides robust genetic evidence for the causal roles of SELE, CDH1, and ALPI in reducing BC risk. The integrative proteomic-genetic-transcriptomic approach identifies potential therapeutic targets and offers new insights into BC pathogenesis, presenting hypotheses for clinical validation.

1 month ago

Journal

CDH1 (Cadherin 1)

simvastatin